Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 361,469	$ 438,680
Accounts receivable	0	1,000
Prepaid expenses and other current assets	8,448	7,965
Research and development incentives receivable	11,368	10,910
Total current assets	381,285	458,555
Property and equipment, net	16,220	3,123
Operating lease right-of-use assets	13,484	14,666
Other assets	6,159	3,448
Total assets	417,148	479,792
Current liabilities:
Accounts payable	7,057	2,721
Accrued expenses and other current liabilities	18,091	14,244
Deferred revenue, current portion	16,404	19,273
Total current liabilities	41,552	36,238
Long-term debt, net of discount	30,232	29,873
Operating lease liabilities, net of current portion	10,997	12,081
Deferred revenue, net of current portion	41,736	52,067
Other long-term liabilities	3,157	3,279
Total liabilities	127,674	133,538
Commitments and contingencies (Note 11)
Shareholders' equity:
Ordinary shares, £0.01 nominal value; 57,820,181 and 55,295,420 shares authorized at September 30, 2022 and December 31, 2021, respectively; 29,678,431 and 29,579,364 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	385	384
Additional paid-in capital	589,679	567,637
Accumulated other comprehensive loss	528	(3,388)
Accumulated deficit	(301,118)	(218,379)
Total shareholders' equity	289,474	346,254
Total liabilities and shareholders' equity	$ 417,148	$ 479,792